绝经后女性辅助激素治疗的进展 - Suppr

Suppr

超能文献

Advances in adjuvant hormonal therapy for postmenopausal women.

作者信息

Strasser-Weippl Kathrin, Goss Paul E

机构信息

First Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria.

出版信息

J Clin Oncol. 2005 Mar 10;23(8):1751-9. doi: 10.1200/JCO.2005.11.038.

DOI:10.1200/JCO.2005.11.038

PMID:15755983

Abstract

摘要

相似文献

Advances in adjuvant hormonal therapy for postmenopausal women.

J Clin Oncol. 2005 Mar 10;23(8):1751-9. doi: 10.1200/JCO.2005.11.038.

[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].

Ugeskr Laeger. 2007 Jan 22;169(4):297-9.

[Neoadjuvant antihormonal treatment of women with breast cancer].

Ugeskr Laeger. 2007 Sep 10;169(37):3077-81.

[Adjuvant treatment of breast cancer. Endocrine therapy].

Ugeskr Laeger. 2007 Sep 10;169(37):3072-6.

Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.

Oncol Nurs Forum. 2008 Jul;35(4):714-21. doi: 10.1188/08.ONF.714-721.

[Future endocrine therapy of breast cancer].

Ugeskr Laeger. 2007 Jan 22;169(4):296.

Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.

Int J Clin Pract. 2006 Jun;60(6):689-93. doi: 10.1111/j.1368-5031.2006.00921.x.

[Treatment guideline for breast cancer and SERM-treatment].

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:636-40.

Adjuvant endocrine treatment of early breast cancer.

Hematol Oncol Clin North Am. 2007 Apr;21(2):223-38. doi: 10.1016/j.hoc.2007.03.002.

[New developments in the hormonal treatment of breast cancer in postmenopausal women].

Bull Cancer. 1999 Oct;86(10):815-20.

引用本文的文献

Editorial: Hormone resistance in cancer.

Front Endocrinol (Lausanne). 2023 Aug 24;14:1272932. doi: 10.3389/fendo.2023.1272932. eCollection 2023.

Aquaporin 5 (AQP5) expression in breast cancer and its clinicopathological characteristics.

PLoS One. 2023 Jan 27;18(1):e0270752. doi: 10.1371/journal.pone.0270752. eCollection 2023.

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target.

Front Oncol. 2021 Nov 4;11:759577. doi: 10.3389/fonc.2021.759577. eCollection 2021.

Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis.

Front Oncol. 2021 Mar 10;11:645698. doi: 10.3389/fonc.2021.645698. eCollection 2021.

Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy.

Front Endocrinol (Lausanne). 2019 May 24;10:245. doi: 10.3389/fendo.2019.00245. eCollection 2019.

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy.

Aging (Albany NY). 2018 Dec 20;10(12):4000-4023. doi: 10.18632/aging.101690.

Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.

Mod Pathol. 2019 Jan;32(1):81-87. doi: 10.1038/s41379-018-0116-5. Epub 2018 Aug 29.

Na+/K+ ATPase activity promotes invasion of endocrine resistant breast cancer cells.

PLoS One. 2018 Mar 28;13(3):e0193779. doi: 10.1371/journal.pone.0193779. eCollection 2018.

ESR1 and endocrine therapy resistance: more than just mutations.

Ann Oncol. 2018 Apr 1;29(4):787-789. doi: 10.1093/annonc/mdy081.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验